Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Methotrexate Combined With Tofacitinib in the Treatment of Active Rheumatoid Arthritis With a Myeloid-stromal Pathotype
NCT06301373Recruiting
- Sponsor
- Sun Yat-sen Memorial Hospital
- Start
- Sep 2024
- Primary completion
- Dec 2029
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Randomised, open-label trial of tofacitinib in rheumatoid arthritis (RA) (2 arms), sponsored by Sun Yat-sen Memorial Hospital. Primary endpoint: American College of Rheumatology 20% improvement criteria at 12 weeks. Started Sep 2024; status: recruiting.
02
Drugs
03
Conditions
rheumatoid arthritis (RA)
Beyond the preview
Go deeper on NCT06301373.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06301373.